10 results on '"Danielsen, Håvard E."'
Search Results
2. Multiple chromosomal monosomies are characteristic of giant cell ependymoma.
- Author
-
Dahlback, Hanne-Sofie S., Brandal, Petter, Krossnes, Bård K., Fric, Radek, Meling, Torstein R., Meza-Zepeda, Leonardo A., Danielsen, Håvard E., and Heim, Sverre
- Subjects
CHROMOSOME abnormalities ,GIANT cell tumors ,CYTOGENETICS ,CANCER relapse ,CANCER invasiveness ,CANCER genetics - Abstract
Summary: Giant cell ependymoma, a rare ependymoma subtype, was recently recognized as a separate diagnostic entity with variations both in malignant potential and course of disease. We analyzed the first supratentorial giant cell ependymoma using G-band karyotyping, DNA ploidy analysis, and array comparative genomic hybridization. The tumor was hypodiploid, and the karyotype showed multiple monosomies. This novel cytogenetic pattern seems specific for giant cell ependymoma as the only previous cytogenetic analysis of a giant cell ependymoma found similar monosomies. We were also able to analyze cytogenetically the subsequent recurrent tumor, phenotypically an anaplastic ependymoma, allowing a first insight into the genetic events involved in disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
3. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas.
- Author
-
Pradhan, Manohar, Abeler, Vera M., Danielsen, Håvard E., Tropé, Claes G., and Risberg, Björn Åke
- Published
- 2006
- Full Text
- View/download PDF
4. A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study.
- Author
-
Kleppe, Andreas, Skrede, Ole-Johan, De Raedt, Sepp, Hveem, Tarjei S, Askautrud, Hanne A, Jacobsen, Jørn E, Church, David N, Nesbakken, Arild, Shepherd, Neil A, Novelli, Marco, Kerr, Rachel, Liestøl, Knut, Kerr, David J, and Danielsen, Håvard E
- Subjects
- *
CLINICAL decision support systems , *TUMOR classification , *CANCER chemotherapy , *COLORECTAL cancer , *ADJUVANT chemotherapy , *CANCER education , *PROGNOSIS , *RESEARCH funding - Abstract
Background: The DoMore-v1-CRC marker was recently developed using deep learning and conventional haematoxylin and eosin-stained tissue sections, and was observed to outperform established molecular and morphological markers of patient outcome after primary colorectal cancer resection. The aim of the present study was to develop a clinical decision support system based on DoMore-v1-CRC and pathological staging markers to facilitate individualised selection of adjuvant treatment.Methods: We estimated cancer-specific survival in subgroups formed by pathological tumour stage (pT<4 or pT4), pathological nodal stage (pN0, pN1, or pN2), number of lymph nodes sampled (≤12 or >12) if not pN2, and DoMore-v1-CRC classification (good, uncertain, or poor prognosis) in 997 patients with stage II or III colorectal cancer considered to have no residual tumour (R0) from two community-based cohorts in Norway and the UK, and used these data to define three risk groups. An external cohort of 1075 patients with stage II or III R0 colorectal cancer from the QUASAR 2 trial was used for validation; these patients were treated with single-agent capecitabine. The proposed risk stratification system was evaluated using Cox regression analysis. We similarly evaluated a risk stratification system intended to reflect current guidelines and clinical practice. The primary outcome was cancer-specific survival.Findings: The new risk stratification system provided a hazard ratio of 10·71 (95% CI 6·39-17·93; p<0·0001) for high-risk versus low-risk patients and 3·06 (1·73-5·42; p=0·0001) for intermediate versus low risk in the primary analysis of the validation cohort. Estimated 3-year cancer-specific survival was 97·2% (95% CI 95·1-98·4; n=445 [41%]) for the low-risk group, 94·8% (91·7-96·7; n=339 [32%]) for the intermediate-risk group, and 77·6% (72·1-82·1; n=291 [27%]) for the high-risk group. The guideline-based risk grouping was observed to be less prognostic and informative (the low-risk group comprised only 142 [13%] of the 1075 patients).Interpretation: Integrating DoMore-v1-CRC and pathological staging markers provided a clinical decision support system that risk stratifies more accurately than its constituent elements, and identifies substantially more patients with stage II and III colorectal cancer with similarly good prognosis as the low-risk group in current guidelines. Avoiding adjuvant chemotherapy in these patients might be safe, and could reduce morbidity, mortality, and treatment costs.Funding: The Research Council of Norway. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.
- Author
-
Lindemann, Kristina, Kildal, Wanja, Kleppe, Andreas, Tobin, Kari Anne R., Pradhan, Manohar, Isaksen, Maria X., Vlatkovic, Ljiljana, Danielsen, Håvard E., Kristensen, Gunnar B., and Askautrud, Hanne A.
- Subjects
- *
RETROSPECTIVE studies , *MOLECULAR biology , *DISEASE relapse , *ENDOMETRIAL tumors , *SURVIVAL analysis (Biometry) , *LONGITUDINAL method - Abstract
The role of molecular classification in patients with low/intermediate risk endometrial cancer (EC) is uncertain. Higher precision in diagnostics will inform the unsettled debate on optimal adjuvant treatment. We aimed to determine the association of molecular profiling with patterns of relapse and survival. This retrospective cohort study included patients referred to The Norwegian Radium Hospital, Oslo University Hospital from 2006–2017. Patients with low/intermediate risk EC were molecularly classified as pathogenic polymerase epsilon (POLE)-mutated, mismatch repair deficient (MMRd), p53 abnormal, or no specific molecular profile (NSMP). The main outcomes were time to recurrence (TTR) and cancer-specific survival (CSS). Of 626 patients, 610 could be molecularly classified. Fifty-seven patients (9%) had POLE-mutated tumors, 202 (33%) had MMRd tumors, 34 (6%) had p53 abnormal tumors and 317 (52%) had NSMP tumors. After median follow-up time of 8.9 years, there was a statistically significant difference in TTR and CSS by molecular groups. Patients with p53 abnormal tumors had poor prognosis, with 10 of the 12 patients with relapse presenting with para-aortic/distant metastases. Patients with POLE mutations had excellent prognosis. In the NSMP group, L1CAM expression was associated with shorter CSS but not TTR. The differences in outcome by molecular groups are driven by differences in relapse frequency and -patterns and demand a higher precision in diagnostics, also in patients with low/intermediate risk EC. Tailored adjuvant treatment strategies need to consider systemic treatment for patients with p53 abnormal tumors and de-escalated treatment for patients with POLE mutated tumors. • Clarifying the role of molecular classification in low/intermediate risk endometrial cancer. • Time to relapse and survival differed signifi cantly by molecular groups. • roboPatients with p53 abnormal tumors had poor outcome. • roboPatients with POLE mutated tumors had excellent survival. • pmMolecular classification is crucial for tailoring of adjuvant treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Chromatin organisation and cancer prognosis: a pan-cancer study.
- Author
-
Kleppe, Andreas, Albregtsen, Fritz, Vlatkovic, Ljiljana, Pradhan, Manohar, Nielsen, Birgitte, Hveem, Tarjei S, Askautrud, Hanne A, Kristensen, Gunnar B, Nesbakken, Arild, Trovik, Jone, Wæhre, Håkon, Tomlinson, Ian, Shepherd, Neil A, Novelli, Marco, Kerr, David J, and Danielsen, Håvard E
- Subjects
- *
CHROMATIN , *CANCER prognosis , *GENE expression , *MACHINE learning , *CANCER invasiveness , *CELL nuclei , *CHROMOSOMES , *COLON tumors , *COMPARATIVE studies , *DEGENERATION (Pathology) , *DIAGNOSTIC imaging , *GENES , *INFORMATION science , *RESEARCH methodology , *MEDICAL cooperation , *COMPUTERS in medicine , *MICROSCOPY , *RESEARCH , *RESEARCH funding , *STAINS & staining (Microscopy) , *TUMOR classification , *EVALUATION research , *PREDICTIVE tests , *TUMOR treatment ,RECTUM tumors ,RESEARCH evaluation - Abstract
Background: Chromatin organisation affects gene expression and regional mutation frequencies and contributes to carcinogenesis. Aberrant organisation of DNA has been correlated with cancer prognosis in analyses of the chromatin component of tumour cell nuclei using image texture analysis. As yet, the methodology has not been sufficiently validated to permit its clinical application. We aimed to define and validate a novel prognostic biomarker for the automatic detection of heterogeneous chromatin organisation.Methods: Machine learning algorithms analysed the chromatin organisation in 461 000 images of tumour cell nuclei stained for DNA from 390 patients (discovery cohort) treated for stage I or II colorectal cancer at the Aker University Hospital (Oslo, Norway). The resulting marker of chromatin heterogeneity, termed Nucleotyping, was subsequently independently validated in six patient cohorts: 442 patients with stage I or II colorectal cancer in the Gloucester Colorectal Cancer Study (UK); 391 patients with stage II colorectal cancer in the QUASAR 2 trial; 246 patients with stage I ovarian carcinoma; 354 patients with uterine sarcoma; 307 patients with prostate carcinoma; and 791 patients with endometrial carcinoma. The primary outcome was cancer-specific survival.Findings: In all patient cohorts, patients with chromatin heterogeneous tumours had worse cancer-specific survival than patients with chromatin homogeneous tumours (univariable analysis hazard ratio [HR] 1·7, 95% CI 1·2-2·5, in the discovery cohort; 1·8, 1·0-3·0, in the Gloucester validation cohort; 2·2, 1·1-4·5, in the QUASAR 2 validation cohort; 3·1, 1·9-5·0, in the ovarian carcinoma cohort; 2·5, 1·8-3·4, in the uterine sarcoma cohort; 2·3, 1·2-4·6, in the prostate carcinoma cohort; and 4·3, 2·8-6·8, in the endometrial carcinoma cohort). After adjusting for established prognostic patient characteristics in multivariable analyses, Nucleotyping was prognostic in all cohorts except for the prostate carcinoma cohort (HR 1·7, 95% CI 1·1-2·5, in the discovery cohort; 1·9, 1·1-3·2, in the Gloucester validation cohort; 2·6, 1·2-5·6, in the QUASAR 2 cohort; 1·8, 1·1-3·0, for ovarian carcinoma; 1·6, 1·0-2·4, for uterine sarcoma; 1·43, 0·68-2·99, for prostate carcinoma; and 1·9, 1·1-3·1, for endometrial carcinoma). Chromatin heterogeneity was a significant predictor of cancer-specific survival in microsatellite unstable (HR 2·9, 95% CI 1·0-8·4) and microsatellite stable (1·8, 1·2-2·7) stage II colorectal cancer, but microsatellite instability was not a significant predictor of outcome in chromatin homogeneous (1·3, 0·7-2·4) or chromatin heterogeneous (0·8, 0·3-2·0) stage II colorectal cancer.Interpretation: The consistent prognostic prediction of Nucleotyping in different biological and technical circumstances suggests that the marker of chromatin heterogeneity can be reliably assessed in routine clinical practice and could be used to objectively assist decision making in a range of clinical settings. An immediate application would be to identify high-risk patients with stage II colorectal cancer who might have greater absolute benefit from adjuvant chemotherapy. Clinical trials are warranted to evaluate the survival benefit and cost-effectiveness of using Nucleotyping to guide treatment decisions in multiple clinical settings.Funding: The Research Council of Norway, the South-Eastern Norway Regional Health Authority, the National Institute for Health Research, and the Wellcome Trust. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. β-Catenin expression in uterine sarcomas and its relation to clinicopathological parameters
- Author
-
Kildal, Wanja, Pradhan, Manohar, Abeler, Vera M., Kristensen, Gunnar B., and Danielsen, Håvard E.
- Subjects
- *
GENE expression , *UTERINE cancer , *TUMOR proteins , *CELLULAR signal transduction , *CHROMOSOME abnormalities , *CARCINOGENESIS , *GENETICS - Abstract
Abstract: Aberrations in the Wnt/β-catenin signalling pathway are suggested as mediators of chromosomal instability and carcinogenesis. β-catenin acts both as a component of the membranous adhesion system, and as a transcription activator in the nucleus. β-Catenin immunoreactivity was evaluated in 353 uterine sarcomas (US) including 231 leiomyosarcomas (LMS), 82 endometrial stromal sarcomas (ESS), 22 adenosarcomas (AS) and 18 undifferentiated uterine sarcomas (UUS). Up-regulated membranous β-catenin was observed in 25% of the LMS (p =0.039), 21% of the ESS (p =0.072) and 39% of the UUS (p =0.025). Cytoplasmic β-catenin was up-regulated in 36% of the LMS (p =0.008) and 33% of the UUS (p =0.028). Nuclear β-catenin expression was observed in 23% of the LMS (p =0.051), 61% of ESS (p =0.628) and in the sarcoma component of 68% of the AS. In patients with LMS, membranous β-catenin was associated with poor crude survival in univariate (p =0.045), but not in multivariate analyses. In patients with ESS, nuclear β-catenin expression was related to spread of tumour (p =0.033), but not to survival. The observation of up-regulated β-catenin expression in US might suggest a so far undocumented role for the Wnt/β-catenin pathway in these malignancies. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
8. β-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: A study in 253 patients
- Author
-
Kildal, Wanja, Risberg, Björn, Abeler, Vera M., Kristensen, Gunnar B., Sudbø, Jon, Nesland, Jahn M., and Danielsen, Håvard E.
- Subjects
- *
CANCER patients , *GENES , *ONCOLOGY , *IMMUNOHISTOCHEMISTRY - Abstract
Abstract: The CTNNB1 gene and its product β-catenin, a regulator of the Wnt signalling pathway, is often mutated and deregulated in human malignancies. Down stream targets of the Wnt signalling pathway are linked to genomic instability. In this study, the impact of β-catenin expression on genomic instability in ovarian carcinoma, as determined by DNA ploidy, was investigated. Expression of β-catenin was examined by immunohistochemistry in 253 ovarian carcinomas. The results were related to genomic instability and clinicopathological features of the patients. Membrane associated staining of β-catenin was detected in nearly all cases with no correlation to clinical parameters. Most of the samples also had cytoplasmic (84%), while only 13% had nuclear β-catenin localisation. A significant association between β-catenin expression (cytoplasmic and nuclear) and histological subtype and degree of differentiation was observed. Nuclear β-catenin was almost exclusively present in endometroid carcinomas. 53% of all endometroid tumours were positive for nuclear β-catenin expression (P <0.0001). Mucinous carcinomas had the highest degree of cytoplasmic β-catenin expression (92%), followed by endometroid (92%), mixed (90%), serous (82%), unclassified adenocarcinomas (81%), carcinomas clear cell and (70%), (P =0.01). Tumours with differentiation grade 1 (16%) and 2 (24%) had higher nuclear β-catenin expression than grade 3 and clear cell carcinomas (6%) (P =0.012). Better prognostic outcome was found for patients with nuclear β-catenin localisation as compared to the cases without (P =0.027). In conclusion, the study showed no correlation between β-catenin expression in ovarian carcinoma and FIGO stage and genomic instability as determined by DNA ploidy status. However, nuclear β-catenin expression was strongly associated with endometroid histological subtype. Finally, in ovarian cancer, although β-catenin staining seems to be of prognostic importance with respect to nuclear staining in univariate analysis, only DNA ploidy status, histological grade and FIGO staging were of independent prognostic significance in multivariate analysis. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
9. Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors—relation to clinicopathologic variables
- Author
-
Kildal, Wanja, Kærn, Janne, Kraggerud, Sigrid Marie, Abeler, Vera M., Sudbø, Jon, Tropè, Claes G., Lothe, Ragnhild A., and Danielsen, Håvard E.
- Subjects
- *
FEMALE reproductive organ tumors , *DEOXYRIBOSE , *ANIMAL infertility , *ANEUPLOIDY , *PLOIDY - Abstract
Malignant ovarian germ cell tumors (mOGCT) affect women in their reproductive years, making fertility-saving treatment important. A reliable prediction of the clinical behavior is essential for an optimal therapeutic approach. The genetic changes and molecular mechanisms underlying these rare tumors remain poorly understood. To address these issues, we performed DNA ploidy analysis by high-resolution image cytometry in a series of 47 mOGCT and correlated the findings with the DNA copy number changes detected by comparative genomic hybridization (CGH) and clinical outcome. Of 47 tumors, 15 were diploid, 14 were tetraploid, 2 were polyploid, and 13 were aneuploid. All the immature teratomas were diploid, in contrast to the dysgerminomas and endodermal sinus tumors. The International Federation of Gynecology and Obstetrics (FIGO) staging, residual tumors after surgery, and DNA ploidy distribution were significant, independent prognostic factors in survival analysis. The study revealed that the number of DNA copy number aberrations was increased in tetraploid and aneuploid tumors as compared to diploid tumors. Furthermore, a high percentage of aneuploid nuclei in a sample were associated with a complex CGH profile of the tumor in question. The present study confirms that DNA aneuploidy assessment by image analysis may be linked to genetic instability, which is detected as genetic aberrations by CGH. DNA ploidy gives significant prognostic information in addition to the clinical stage in mOGCT with FIGO stage II–IV. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
10. Familial/Bilateral and Sporadic Testicular Germ Cell Tumors Show Frequent Genetic Changes at Loci with Suggestive Linkage Evidence.
- Author
-
Skotheim, Rolf I, Kraggerud, Sigrid M, Fosså, Sophie D, Stenwig, Anna E, Gedde-Dahl jr, Tobias, Danielsen, Håvard E, Jakobsen, Kjetill S, and Lothe, Ragnhild A
- Subjects
- *
GERM cell tumors , *ALLELES , *FAMILIAL diseases - Abstract
Testicular germ cell tumor (TGCT) is the most common tumor type among adolescent and young adult males. Familial clustering and bilateral disease are suggestive of a genetic predisposition among a subgroup of these patients, but susceptibility genes for testicular cancer have not yet been identified. However, suggestive linkage between disease and genetic markers has been reported at loci on chromosome arms 3q, 5q, 12q, 18q, and Xq. We have analyzed primary familial/bilateral ( n=20) and sporadic ( n=27) TGCTs, including 28 seminomas and 19 nonseminomas, for allelic imbalance (AI) within the autosomal regions. DNA from all tumors were analyzed by fluorescent polymerase chain reaction of 22 polymorphic loci at 3q27-ter, 5q13–35.1, 12q21-ter, and 18q12–ter. All tumor genotypes were evaluated against their corresponding constitutional genotypes. The percentages of TGCTs with genetic changes at 3q, 5q, 12q, and 18q, were 79%, 36%, 53% and 43%, respectively. The frequencies at 3q and 12q in nonseminomas were significantly higher than in seminomas ( P=.003 and P=.004). In order to evaluate changes at hemizygous Xq loci, five loci were analyzed by co-amplification with an autosomal reference marker known to reveal retained heterozygosity in the tumor DNA. Gain of Xq sequences was seen in more than 50% of the tumors. The degree of amplification varied among the loci in each of five tumors, and based on these breakpoints, a common region of overlapping gains was found at Xq28. No significant differences were found between the frequencies of genetic changes in familial/bilateral versus sporadic tumors, an observation speaking in disfavor of the existence of a single susceptibility gene for TGCT in any of the analyzed regions. Our data suggest that gain of genetic material at distal Xq and losses at 5q and 18q contribute to establishment of seminomas, whereas imbalances at 3q as well as gain at distal part of 12q are associated with further progression into... [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.